ncRNAs and Cancer Immunotherapy

A special issue of Non-Coding RNA (ISSN 2311-553X).

Deadline for manuscript submissions: closed (31 March 2017) | Viewed by 11421

Special Issue Editor

Guest Editor
Department of Oncology, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy
Interests: acute myeloid leukemia; normal and leukemic stem cells; hematopoietic differentiation; cell differentiation therapy; targeted therapy; CD123 targeting
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Non-coding RNA is now accepting submissions for a Special Issue on the biology of ncRNAs and on cancer immunotherapy. This Special Issue is guest-edited by Dr. Ugo Testa from the “Istituto Superiore di Sanità” in Rome, Italy, and will include commissioned topical reviews written by leaders in the field. Accepted papers are published online immediately after copy editing. Non-Coding RNA is an Open Access journal, and there are no Article Processing Charges (APCs) for papers submitted in 2016.

The key role of specific miRNAs for the regulation of immune cell development and function has been firmly established and their association with different human neoplastic diseases has also been demonstrated. Changes in the levels of some of these miRNAs determine deregulation in important immune pathways involved in the control of tumor growth and represent important pathogenetic mechanisms of cancer development and/or progression. The understanding of the inhibitory effect exerted by these miRNAs on the anti-tumor immune pathways is important not only at the basic level for a better understanding of tumor pathogenesis, but also at the translational level for the identification of potential targetable pathways for therapeutic purposes.

We will consider Research, Methods, and Review manuscripts of exceptional interest on the following topics;

  • Regulation of tumor myeloid-derived suppressor cells by miRNAs
  • Regulation of Programmed Cell Death by miRNA
  • Immune check inhibitors and miRNAs
  • Targeting miRNAs as a therapeutic strategy to modulate anti-tumor immune response
  • miRNA immunotherapeutic targets in colorectal cancer and melanoma
  • The emerging role of exosomes in the control of immunological responses to tumors
  • Enhancing adoptive T-cell anti-cancer immunotherapy with miRNA therapeutics
  • miRNAs as modulators of the response to anti-tumor immunotherapy
  • Targeting the tumor microenvironment

Dr. Ugo Testa
Guest Editor

Do not miss out the deadline for submissions: 31 March 2017.

Please use the online submission system and indicate in your cover letter that you would like to have your manuscript considered for the Special Issue “ncRNAs and Cancer Immunotherapy”. If you would like to enquire about the suitability of your article for this Special Issue, please email your pre-submission enquiry to Dr. Ugo Testa at [email protected] and cc the ncRNA Editorial Office at [email protected].

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Non-Coding RNA is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • ncRNA
  • Immunotherapy
  • miRNA
  • Anti-cancer
  • T-cell miRNA

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


2856 KiB  
miR-146 and miR-155: Two Key Modulators of Immune Response and Tumor Development
by Ugo Testa, Elvira Pelosi, Germana Castelli and Catherine Labbaye
Non-Coding RNA 2017, 3(3), 22; - 26 Jun 2017
Cited by 186 | Viewed by 11005
MicroRNAs (miRNAs or miRs) are a class of evolutionarily-conserved small, regulatory non-coding RNAs, 19–3 nucleotides in length, that negatively regulate protein coding gene transcripts’ expression. miR-146 (146a and 146b) and miR-155 are among the first and most studied miRs for their multiple roles [...] Read more.
MicroRNAs (miRNAs or miRs) are a class of evolutionarily-conserved small, regulatory non-coding RNAs, 19–3 nucleotides in length, that negatively regulate protein coding gene transcripts’ expression. miR-146 (146a and 146b) and miR-155 are among the first and most studied miRs for their multiple roles in the control of the innate and adaptive immune processes and for their deregulation and oncogenic role in some tumors. In the present review, we have focused on the recent acquisitions about the key role played by miR-146a, miR-146b and miR-155 in the control of the immune system and in myeloid tumorigenesis. Growing experimental evidence indicates an opposite role of miR-146a with respect to miR-155 in the fine regulation of many steps of the immune response, acting at the level of the various cell types involved in innate and adaptive immune mechanisms. The demonstration that miR-155 overexpression plays a key pathogenic role in some lymphomas and acute myeloid leukemias has led to the development of an antagomir-based approach as a new promising therapeutic strategy. Full article
(This article belongs to the Special Issue ncRNAs and Cancer Immunotherapy)
Show Figures

Figure 1

Back to TopTop